Filing Flows › Pfizer (PFE) › Q2 2025
Pfizer (PFE) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Pfizer (PFE) reported revenue of $14.7B for the second quarter 2025 (Q2 2025), +10% from a year earlier and +7% from the quarter before. Operating margin was 20.9%, net earnings $2.9B (19.9% of revenue).
Pfizer, Q2 2025: revenue $14.7B (+10% year over year), operating margin 20.9%, net earnings $2.9B, operating cash flow −$582M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.7B | +7% | +10% |
| Operating profit | $3.1B | +10% | — |
| Net earnings | $2.9B | -2% | 71× |
| Operating cash flow | −$582M | -125% | — |
What changed
Revenue was $14.7B in Q2 2025, up 10% year over year and up 7% from the previous quarter.
Operating profit was $3.1B, a 20.9% margin (up 21.6 points year over year). Total costs fell 13% while revenue rose 10%. The fastest-growing cost line was Cost of revenue (+14%). Net earnings were $2.9B, up 6998% year over year. The effective tax rate was 4.6%.
Operating cash flow was −$0.58B. Non-cash charges added back $1.6B of depreciation and amortization and $0.20B of share-based compensation. Working capital and other items used $5.3B. Capital expenditures of $0.62B exceeded it, leaving free cash flow of −$1.2B.
Questions
What was Pfizer's revenue in the second quarter 2025?
Pfizer (PFE) reported revenue of $14.7B for the second quarter 2025 (Q2 2025), +10% from a year earlier and +7% from the quarter before.
Was Pfizer profitable in the second quarter 2025?
Operating profit was $3.1B (20.9% of revenue) and net earnings $2.9B.
Source: Pfizer 10-Q on SEC EDGAR.